Compare FCF & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCF | TRVI |
|---|---|---|
| Founded | 1934 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.6B |
| IPO Year | 1994 | 2019 |
| Metric | FCF | TRVI |
|---|---|---|
| Price | $20.29 | $11.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $24.07 | ★ $28.18 |
| AVG Volume (30 Days) | 1.0M | ★ 2.4M |
| Earning Date | 10-27-2026 | 11-12-2026 |
| Dividend Yield | ★ 2.77% | N/A |
| EPS Growth | 5.76 | ★ 31.91 |
| EPS | ★ 0.81 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.49 | N/A |
| Revenue Next Year | $5.68 | N/A |
| P/E Ratio | $24.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.00 | $9.82 |
| 52 Week High | $22.34 | $20.22 |
| Indicator | FCF | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 46.63 | 21.29 |
| Support Level | $19.85 | $9.97 |
| Resistance Level | $20.87 | $13.55 |
| Average True Range (ATR) | 0.33 | 0.63 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 67.38 | 8.52 |
First Commonwealth Financial Corp functions in the financial services sector in the United States. Through its subsidiary, it offers a range of consumer and commercial banking services such as personal checking accounts, interest-earning checking accounts, savings accounts, insured money market accounts, investment certificates, fixed & variable rate certificates of deposit, and various kinds of loans. It also provides trust and wealth management services and offers insurance products. The company earns the majority of its revenue through net interest income.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.